"the preprint of our work on targeting CD25+ #lymphoma cells with the ADC camidanlumab tesirine is now available in ⁦@biorxivpreprint⁩ ⁦@IOR_Bellinzona⁩ ⁦@USI_en⁩ ⁦@EnteOspedaliero⁩ ⁦@AnastasiosStat2⁩ ⁦@CascioneLuciano⁩ https://t.co/MxYXwmKWUe"